16 October 2014Americas

US Supreme Court split on Teva case

The US Supreme Court was split yesterday (October 15) after hearing arguments in a high-profile case that will determine whether generic drug companies are free to market a cheaper version of Teva’s blockbuster multiple sclerosis drug.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Teva asks US Supreme Court to stay ruling in Copaxone case

8 April 2014 Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.

US Supreme Court hears Teva arguments in Copaxone case

15 October 2014 The highest court in the US will hear a dispute today (October 15) between pharmaceutical company Teva and generic rivals that are looking to market versions of its multiple sclerosis drug Copaxone (glatiramer acetate).

More on this story

Teva asks US Supreme Court to stay ruling in Copaxone case

8 April 2014 Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.

US Supreme Court hears Teva arguments in Copaxone case

15 October 2014 The highest court in the US will hear a dispute today (October 15) between pharmaceutical company Teva and generic rivals that are looking to market versions of its multiple sclerosis drug Copaxone (glatiramer acetate).

More on this story

Teva asks US Supreme Court to stay ruling in Copaxone case

8 April 2014 Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.

US Supreme Court hears Teva arguments in Copaxone case

15 October 2014 The highest court in the US will hear a dispute today (October 15) between pharmaceutical company Teva and generic rivals that are looking to market versions of its multiple sclerosis drug Copaxone (glatiramer acetate).

More features

‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course

Drug approvals up but global innovation declines

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute

Preventative IP for preventative pharma healthcare

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel